Women are increasingly using testosterone to try to manage menopause-related symptoms, including sexual desire problems and, in some cases, fatigue, mood changes and brain fog. Reporting from multiple outlets cites new analyses showing a substantial rise in prescriptions in recent years, alongside ongoing debate among experts about what testosterone can reliably improve.

A key point in the coverage is that testosterone is not approved by the FDA specifically for use in females, which leaves many prescriptions off-label. Clinical guidance supported by medical groups, including The Menopause Society, focuses on testosterone therapy for hypoactive sexual desire disorder (HSDD) in postmenopausal women. Several sources note that testosterone levels decline with aging rather than due to menopause itself, and experts say evidence does not support testosterone for most other menopause symptoms.

Other outlets highlight practical barriers that can accompany off-label prescribing, including pharmacy delays or denials when products require dose customization for safe dispensing. The FDA is described as calling for more data and encouraging further studies that could support future approval of female-specific testosterone products. More research is underway, with ongoing clinical trials exploring potential benefits beyond libido.